FDA OK's BI's Gilotrif in NSCLC, with Qiagen's therascreen Dx
This article was originally published in Scrip
Executive Summary
Patients with metastatic non-small cell lung cancer (NSCLC) with certain epidermal growth factor receptor (EGFR) mutations have a new treatment option after the FDA's 12 July approval of Boehringer Ingelheim's new drug application (NDA) to market Gilotrif (afatinib).